Frontier Medicines is a precision medicine biopharmaceutical company focusing on developing therapies against previously "undruggable" targets. Founded by Chris Varma, Ph.D., the company is headquartered in South San Francisco, California, and Boston, Massachusetts. Since its founding, Frontier Medicines has raised over $147 million through various financing rounds, including a $67 million Series A and an $80 million Series C. The company employs a proprietary chemoproteomics platform coupled with machine learning to pioneer new treatments primarily in oncology and immunology.
| Attribute | Information |
|---|---|
| Founding Date | 2019 |
| Headquarters | South San Francisco, CA, and Boston, MA |
| Founders | Chris Varma, Ph.D. |
| Revenue | Not publicly disclosed |
| Profits | Not publicly disclosed |
| Key Investors | Deerfield Management, Droia Oncology Ventures |
| Industry | Biopharmaceuticals |
| Number of Employees | Not publicly disclosed |
Founded in 2019 by Chris Varma, Ph.D., Frontier Medicines began with a vision to exploit novel targets in the proteome that were traditionally undruggable. The company’s early focus was to marry chemoproteomics with advanced computational methods to identify binding pockets in proteins that lacked classical binding sites, using insights from Daniel Nomura, a chemical biologist at the University of California, Berkeley. This approach aimed to radically simplify the discovery process of small-molecule drugs. The formative years involved establishing a robust pipeline of potential drugs, particularly in oncology and immunology, and building strategic partnerships with prominent industry players like AbbVie.
Frontier Medicines operates as a leader in precision medicine with its chemoproteomics and machine learning technologies, striving to "drug the undruggable". This innovative approach allows for targeting complex protein structures, addressing key disease areas such as cancer. Highlights of their achievements include:
Currently, Frontier Medicines holds a strong position within the biopharmaceutical sector by targeting diseases traditionally considered untreatable. Its operations are centered around clinical-stage development of precision medicines using their proprietary chemoproteomics platform. By focusing on genetically-defined patient groups, Frontier Medicines is addressing a critical unmet need in oncology. The company's differentiation lies in its ability to target both the ON and OFF forms of KRAS G12C, a notable cancer-driving mutation, setting it apart from existing competitors in the KRAS inhibitor arena.
Frontier Medicines stands out in the biopharmaceutical industry with its innovative approach to drug discovery targeting previously impenetrable disease-causing proteins. With substantial funding and partnerships, particularly with AbbVie, Frontier Medicines is positioned to advance its modality of treating cancer through precision medicines. As it continues to progress its clinical-stage assets like FMC-376 and expand its chemoproteomics platform, Frontier remains at the forefront of transforming therapies for genetically-defined diseases, poised for significant growth in the future.